Top Industry News

GSK has agreed to acquire Nuvalent, a Boston-based clinical-stage bio/pharmaceutical company focused on oncology therapies, for $10.6 billion.  Nuvalent is developing small molecules that are designed to overcome the limitations of existing therapies for clinically…

Incyte has agreed to acquire Vega Therapeutics, a South San Francisco, California-based bio/pharmaceutical company developing antibody therapies for rare blood disorders and a subsidiary of Star Therapeutics, a South San Francisco-based bio/pharmaceutical company developing antibodies for hematologic and immunologic diseases, in a…

Johnson & Johnson has agreed to acquire Firefly Bio, a South San Francisco, California-based bio/pharmaceutical company specializing in degrader antibody conjugates (DACs), for $1 billion.   The acquisition includes Firefly Bio’s Firelink proprietary platform for producing DACs, a new modality for cancer treatments, which…

The latest from CDMOs, CMOs, and suppliers featuring WuXi Biologics, PharmaBlock, Fujifilm, Axplora, Cytovance Biologics, Northway Biotech, Schott Pharma, Barentz, and Symeres.   Chemicals/Chemical API Manufacturing * PharmaBlock Commissions Pilot-Scale Peptide Plant * Axplora Consolidates Ursodeoxycholic Acid Production at Indian Site * Barentz Opens Pharma Office in…

A roundup of news from the large and mid-sized bio/pharmaceutical companies featuring Gilead Sciences, Roche, Hikma Pharmaceuticals, Alynylam, Novartis, GSK, Servier and Sanofi. Highlights below.   For the latest news roundup on small…

The latest from small and Emerging Pharma companies featuring Apnimed, SonoThera, Ethyreal Bio, City Therapeutics and Treeline Biosciences/Standard Biotools.  For news on the large and mid-sized bio/pharmaceutical companies, see Global Briefs. …

Pfizer and Innovent Biologics, a Suzhou, China-based bio/pharmaceutical company, have entered into an agreement for the research and development of 12 early-stage and de novo cancer medicines, in a deal worth up to $10 billion ($650…

Eli Lilly and Company and Hanmi Pharm. Co., a Seoul, South Korea-based bio/pharmaceutical company, have entered into a license agreement for the development, manufacturing, and commercialization of Hanmi’s drug candidate, sonefpeglutide, in a…

Servier, a French bio/pharmaceutical company, has agreed to acquire the muscular dystrophy business of Edgewise Therapeutics, a bio/pharmaceutical company focused on serious muscle disorders, for up to $2.65 billion ($1.55 billion…

The latest from CDMOs, CMOs, and suppliers featuring Recipharm, Ashland, VectorBuilder, West Pharmaceutical Services, Ardena, Dow, Univar Solutions and Veranova.   Biologics Manufacturing * VectorBuilder Investing $50 Million in Genetic Medicine Mfg and R&D Center Formulation Development/Drug Product Manufacturing * Recipharm Adds New Blow–Fill–Seal Line *…